139 related articles for article (PubMed ID: 33768996)
41. [Screening and identification of microRNAs related to acquired gefitinib-resistance in lung adenocarcinoma cell lines].
Qin X; Liu B; Li Y; You J; Zhou Q
Zhongguo Fei Ai Za Zhi; 2011 Jun; 14(6):478-83. PubMed ID: 21645449
[TBL] [Abstract][Full Text] [Related]
42. Inhibition of microRNA-196a might reverse cisplatin resistance of A549/DDP non-small-cell lung cancer cell line.
Li JH; Luo N; Zhong MZ; Xiao ZQ; Wang JX; Yao XY; Peng Y; Cao J
Tumour Biol; 2016 Feb; 37(2):2387-94. PubMed ID: 26376998
[TBL] [Abstract][Full Text] [Related]
43. The long non-coding RNA SNHG5 regulates gefitinib resistance in lung adenocarcinoma cells by targetting
Wang Z; Pan L; Yu H; Wang Y
Biosci Rep; 2018 Aug; 38(4):. PubMed ID: 29592872
[TBL] [Abstract][Full Text] [Related]
44. Breast cancer resistance protein BCRP/ABCG2 regulatory microRNAs (hsa-miR-328, -519c and -520h) and their differential expression in stem-like ABCG2+ cancer cells.
Li X; Pan YZ; Seigel GM; Hu ZH; Huang M; Yu AM
Biochem Pharmacol; 2011 Mar; 81(6):783-92. PubMed ID: 21219875
[TBL] [Abstract][Full Text] [Related]
45. let‑7 and miR‑17 promote self‑renewal and drive gefitinib resistance in non‑small cell lung cancer.
Yin J; Hu W; Pan L; Fu W; Dai L; Jiang Z; Zhang F; Zhao J
Oncol Rep; 2019 Aug; 42(2):495-508. PubMed ID: 31233201
[TBL] [Abstract][Full Text] [Related]
46. A novel circular RNA hsa_circRNA_103809/miR-377-3p/GOT1 pathway regulates cisplatin-resistance in non-small cell lung cancer (NSCLC).
Zhu X; Han J; Lan H; Lin Q; Wang Y; Sun X
BMC Cancer; 2020 Dec; 20(1):1190. PubMed ID: 33276753
[TBL] [Abstract][Full Text] [Related]
47. [Drug resistance mechanism of non small cell lung cancer PC9/AB2 cell line with acquired drug resistance to gefitinib].
Ju LX; Zhou CC; Tang L; Zhao YM; Yang XJ; Su B; Meng SY; Li W; Yan LH; Ding YM
Zhonghua Jie He He Hu Xi Za Zhi; 2010 May; 33(5):354-8. PubMed ID: 20646614
[TBL] [Abstract][Full Text] [Related]
48. A novel circular RNA, hsa_circ_0043278, acts as a potential biomarker and promotes non-small cell lung cancer cell proliferation and migration by regulating miR-520f.
Cui J; Li W; Liu G; Chen X; Gao X; Lu H; Lin D
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):810-821. PubMed ID: 30873868
[TBL] [Abstract][Full Text] [Related]
49. Mig-6 overcomes gefitinib resistance by inhibiting EGFR/ERK pathway in non-small cell lung cancer cell lines.
Li ZX; Qu LY; Wen H; Zhong HS; Xu K; Qiu XS; Wang EH
Int J Clin Exp Pathol; 2014; 7(10):7304-11. PubMed ID: 25400829
[TBL] [Abstract][Full Text] [Related]
50. Chronic treatment of non-small-cell lung cancer cells with gefitinib leads to an epigenetic loss of epithelial properties associated with reductions in microRNA-155 and -200c.
Narita M; Shimura E; Nagasawa A; Aiuchi T; Suda Y; Hamada Y; Ikegami D; Iwasawa C; Arakawa K; Igarashi K; Kuzumaki N; Yoshioka Y; Ochiya T; Takeshima H; Ushijima T; Narita M
PLoS One; 2017; 12(2):e0172115. PubMed ID: 28225782
[TBL] [Abstract][Full Text] [Related]
51. Cancer exosomal microRNAs from gefitinib-resistant lung cancer cells cause therapeutic resistance in gefitinib-sensitive cells.
Azuma Y; Yokobori T; Mogi A; Yajima T; Kosaka T; Iijima M; Shimizu K; Shirabe K; Kuwano H
Surg Today; 2020 Sep; 50(9):1099-1106. PubMed ID: 32052182
[TBL] [Abstract][Full Text] [Related]
52. Circ_0067934 promotes non-small cell lung cancer development by regulating miR-1182/KLF8 axis and activating Wnt/β-catenin pathway.
Zhao M; Ma W; Ma C
Biomed Pharmacother; 2020 Sep; 129():110461. PubMed ID: 32768951
[TBL] [Abstract][Full Text] [Related]
53. Correlations of hsa_circ_0046264 expression with onset, pathological stage and chemotherapy resistance of lung cancer.
Liu ZH; Yang SZ; Chen XT; Shao MR; Dong SY; Zhou SY; Liu L
Eur Rev Med Pharmacol Sci; 2020 Sep; 24(18):9511-9521. PubMed ID: 33015793
[TBL] [Abstract][Full Text] [Related]
54. Reciprocal regulation of miR-206 and IL-6/STAT3 pathway mediates IL6-induced gefitinib resistance in EGFR-mutant lung cancer cells.
Yang Y; Wang W; Chang H; Han Z; Yu X; Zhang T
J Cell Mol Med; 2019 Nov; 23(11):7331-7341. PubMed ID: 31507089
[TBL] [Abstract][Full Text] [Related]
55. Targeting Adenine Nucleotide Translocase-2 (ANT2) to Overcome Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer.
Jang JY; Kim YG; Nam SJ; Keam B; Kim TM; Jeon YK; Kim CW
Mol Cancer Ther; 2016 Jun; 15(6):1387-96. PubMed ID: 26883272
[TBL] [Abstract][Full Text] [Related]
56. Suppression of Circular RNA Hsa_circ_0109320 Attenuates Non-Small Cell Lung Cancer Progression via MiR-595/E2F7 Axis.
Bai Q; Li L; Chen F; Zhu J; Cao L; Yang Y; Zhong F
Med Sci Monit; 2020 Jun; 26():e921200. PubMed ID: 32508344
[TBL] [Abstract][Full Text] [Related]
57. Circular RNA hsa_circ_0004015 regulates the proliferation, invasion, and TKI drug resistance of non-small cell lung cancer by miR-1183/PDPK1 signaling pathway.
Zhou Y; Zheng X; Xu B; Chen L; Wang Q; Deng H; Jiang J
Biochem Biophys Res Commun; 2019 Jan; 508(2):527-535. PubMed ID: 30509491
[TBL] [Abstract][Full Text] [Related]
58. MiR-134/487b/655 cluster regulates TGF-β-induced epithelial-mesenchymal transition and drug resistance to gefitinib by targeting MAGI2 in lung adenocarcinoma cells.
Kitamura K; Seike M; Okano T; Matsuda K; Miyanaga A; Mizutani H; Noro R; Minegishi Y; Kubota K; Gemma A
Mol Cancer Ther; 2014 Feb; 13(2):444-53. PubMed ID: 24258346
[TBL] [Abstract][Full Text] [Related]
59. Oct4 plays a crucial role in the maintenance of gefitinib-resistant lung cancer stem cells.
Kobayashi I; Takahashi F; Nurwidya F; Nara T; Hashimoto M; Murakami A; Yagishita S; Tajima K; Hidayat M; Shimada N; Suina K; Yoshioka Y; Sasaki S; Moriyama M; Moriyama H; Takahashi K
Biochem Biophys Res Commun; 2016 Apr; 473(1):125-132. PubMed ID: 26996130
[TBL] [Abstract][Full Text] [Related]
60. Role of FBXW7 in the quiescence of gefitinib-resistant lung cancer stem cells in EGFR-mutant non-small cell lung cancer.
Hidayat M; Mitsuishi Y; Takahashi F; Tajima K; Yae T; Miyahara K; Hayakawa D; Winardi W; Ihara H; Koinuma Y; Wirawan A; Nurwidya F; Kato M; Kobayashi I; Sasaki S; Takamochi K; Hayashi T; Suehara Y; Moriyama M; Moriyama H; Habu S; Takahashi K
Bosn J Basic Med Sci; 2019 Nov; 19(4):355-367. PubMed ID: 31202256
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]